Multiple myeloma Trials in Fairway, United States
Conditions / Multiple myeloma / Fairway, United States
Clinical trials for Multiple myeloma investigate a range of treatment strategies and patient populations.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04184050 | Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT01830816 | Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment | COMPLETED | PHASE1 |
| NCT03567616 | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | TERMINATED | PHASE2 |
| NCT01660633 | Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation | COMPLETED | PHASE2 |
| NCT03424603 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | COMPLETED | PHASE1 |
| NCT05346835 | Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma | AVAILABLE | — |
| NCT01946477 | Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting | COMPLETED | PHASE2 |
| NCT02773030 | A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT03525678 | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody | COMPLETED | PHASE2 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | ACTIVE_NOT_RECRUITING | — |